TALS - New analysis confirms efficacy of Talaris living donor kidney transplant drug

High-resolution allele typing at six loci found Talaris Therapeutics' (NASDAQ:TALS) FCR001 induced durable immune tolerance in patients undergoing living donor kidney transplant. The tolerance was seen in highly mismatched related and unrelated recipients. In DNA samples from a phase 2 trial, 21 of 29 donor/recipient pairs had 6/12 or more HLA allele mismatching. In a second group, two of the three pairs had 5/10 or more mismatching. After FCR011 treatment, FCR001 led to withdrawal of  immunosuppression drugs in 25 of the 32 participants. Read about an early clinical update of a phase 3 trial for FCR001.

For further details see:

New analysis confirms efficacy of Talaris living donor kidney transplant drug